QuickView for perhexiline (compound)

Perhexilinum [INN-Latin]; Prestwick0_000286; Prestwick1_000286; KBio3_002618; DivK1c_000542; KBio2_000353; 2-(2,2-dicyclohexylethyl)piperidine; KBio2_005489; KBioSS_000353; NINDS_000542.
show more »

Perhexilinum [INN-Latin]; Prestwick0_000286; Prestwick1_000286; KBio3_002618; DivK1c_000542; KBio2_000353; 2-(2,2-dicyclohexylethyl)piperidine; KBio2_005489; KBioSS_000353; NINDS_000542; SPBio_001358; 6621-47-2; Perhexilene; Perhexiline; Spectrum2_001539; Perhexilina [INN-Spanish]; Spectrum4_000173; KBio2_002921; Spectrum_000013; Spectrum3_001579; KBio1_000542; EINECS 229-569-5; CHEBI:35553; KBioGR_000685; SPBio_002411; Piperidine, 2-(2,2-dicyclohexylethyl)-
show less «

2-(2,2-Dicyclohexylethyl)piperidine; Perhexilene; Perhexilinum [INN-Latin]; (-)-2-(2,2-Dicyclohexylethyl)piperidine; Perhexilline; Perhexilina [INN-Spanish]; (+)-2-(2,2-Dicyclohexylethyl)piperidine

Used in the treatment of unresponsive or refractory angina. Perhexiline increases glucose metabolism at the expense of free-fatty-acid metabolism, enhancing oxygen efficiency during myocardial ischaemia. Perhexiline also potentiates platelet responsiveness to nitric oxide both in patients with angina and patients with acute coronary syndrome. The p...
show more »

Used in the treatment of unresponsive or refractory angina. Perhexiline increases glucose metabolism at the expense of free-fatty-acid metabolism, enhancing oxygen efficiency during myocardial ischaemia. Perhexiline also potentiates platelet responsiveness to nitric oxide both in patients with angina and patients with acute coronary syndrome. The predominant mechanism of this particular perhexiline effect is an increase in platelet cGMP responsiveness. Perhexiline also may reduce the potential for nitric oxide clearance by neutrophil-derived oxygen. Perhexiline relieves symptoms of angina, improves exercise tolerance, and increases the workload needed to induce ischaemia when used as monotherapy. The primary therapeutic roles for perhexiline are as short-term therapy (less than 3 months duration) in patients with severe ischaemia awaiting coronary revascularisation or long-term therapy in patients with ischaemic symptoms refractory to other therapeutic measures.
show less «

Perhexiline binds to the mitochondrial enzyme carnitine palmitoyltransferase (CPT)-1 and CPT-2. It acts by shifting myocardial substrate utilisation from long chain fatty acids to carbohydrates through inhibition of CPT-1 and, to a lesser extent, CPT-2, resulting in increased glucose and lactate utilization. This results in increased ATP production...
show more »

Perhexiline binds to the mitochondrial enzyme carnitine palmitoyltransferase (CPT)-1 and CPT-2. It acts by shifting myocardial substrate utilisation from long chain fatty acids to carbohydrates through inhibition of CPT-1 and, to a lesser extent, CPT-2, resulting in increased glucose and lactate utilization. This results in increased ATP production for the same O2 consumption as before and consequently increases myocardial efficiency.
show less «